Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
00
Trial Sponsor
Clinical Trial Start Date
2022
0Primary Completion Date
2026
0Study Completion Date
2039
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
FT5960
Vincristine0
Rituximab0
Prednisone0
Doxorubicin0
Cyclophosphamide0
Bendamustine0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma0
Last Updated
July 6, 2023
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
